Physician profile
John E Brusky
NPI 1669455648
$8,317.34
in general payments reported to CMS, 2019-2025
36 companies · $194 in 2025
The $194 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,001 · 2020: $1,312 · 2021: $1,089 · 2022: $582 · 2023: $1,001 · 2024: $1,139 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,333.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertiflex, INC. | $1,782.09 | 2019 | |
| Boston Scientific Corporation | $1,150.98 | 2019-2025 | General - Pain Management, Patient Trial Kit, Wavewriter Alpha Prime 16 |
| Nevro Corp. | $914.86 | 2019-2023 | Senza |
| Collegium Pharmaceutical, INC. | $882.11 | 2019-2025 | Belbuca, Xtampza, Nucynta |
| Abbott Laboratories | $818.07 | 2020-2025 | Proclaim |
| Tersera Therapeutics LLC | $368.27 | 2019-2025 | Prialt |
| Medtronic, INC. | $294.11 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $288.25 | 2019-2025 | Relistor |
| Spr Therapeutics, INC | $252.99 | 2019-2024 | Sprint Pns System |
| Medtronic USA, INC. | $231.37 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $196.81 | 2019-2021 | |
| Pfizer INC. | $149.54 | 2019-2020 | |
| Pacira Therapeutics, INC. | $99.70 | 2019-2021 | |
| Fidia Pharma USA INC. | $84.70 | 2019-2024 | Triluron, Hymovis, Hyalgan |
| Scilex Pharmaceuticals INC. | $82.22 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $75.77 | 2021-2023 | Loreev Xr, Gralise |
| Novartis Pharmaceuticals Corporation | $73.80 | 2019 | |
| Piramal Critical Care | $72.89 | 2024 | |
| Saluda Medical Americas, INC. | $69.56 | 2024 | Evoke |
| Sentynl Therapeutics, INC. | $57.99 | 2019 | |
| Nalu Medical, INC. | $49.06 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $39.87 | 2019-2020 | |
| Neuronetics, INC. | $36.20 | 2022 | |
| Supernus Pharmaceuticals, INC. | $33.47 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $25.91 | 2025 | |
| Assertio Therapeutics, INC. | $24.37 | 2019 | |
| Orthogenrx INC. | $23.38 | 2021 | |
| Shionogi INC | $19.75 | 2019 | |
| Baudax Bio INC. | $17.31 | 2020 | |
| Electronic Waveform Lab, INC. | $16.98 | 2019 | |
| Ferring Pharmaceuticals INC. | $16.32 | 2022 | |
| Davol INC. | $15.62 | 2024 | Arista Ah Flexitip |
| Mdd US Operations, LLC | $15.57 | 2020 | |
| Daiichi Sankyo INC. | $15.38 | 2019 | |
| Grt US Holding, INC. | $11.65 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Brusky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.